<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27455" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Portal-Systemic Encephalopathy(Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khan</surname>
            <given-names>Muhammad A.</given-names>
          </name>
          <aff>Montefiore Medical Center/Albert Einstein College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anjum</surname>
            <given-names>Fatima</given-names>
          </name>
          <aff>Temple University, Lewis Katz School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Khan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Fatima Anjum declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27455.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Portosystemic encephalopathy, also known as hepatic encephalopathy (HE), is defined as a neuropsychiatric syndrome that can develop in patients with a portosystemic shunt. A patient with liver dysfunction having neuropsychiatric signs and&#x000a0;symptoms should be considered as having hepatic encephalopathy&#x000a0;until&#x000a0;proven otherwise.<xref ref-type="bibr" rid="article-27455.r1">[1]</xref>&#x000a0;</p>
        <p>In a portosystemic shunt, blood from the splanchnic venous circulation is shunted to collateral venous drainage instead of passing through hepatic sinusoids. A portosystemic shunt can be congenital or acquired. Congenital portosystemic shunts are rare and could be extrahepatic or intrahepatic. A portosystemic shunt is called congenital when there is no history of cirrhosis, portal hypertension, or portal vein thrombosis. The acquired portosystemic shunt is usually caused by portal hypertension due to cirrhosis of the liver in end-stage liver disease. Acquired and&#x000a0;congenital&#x000a0;portosystemic shunt both can present with hepatic&#x000a0;encephalopathy.<xref ref-type="bibr" rid="article-27455.r2">[2]</xref>&#x000a0;</p>
        <p>Due to the shunt, ammonia, and other neurotoxins that usually get metabolized in the liver, bypass and cross the blood-brain barrier leading to the accumulation of neurotoxins in the brain, causing cognitive and psychomotor disturbances.<xref ref-type="bibr" rid="article-27455.r3">[3]</xref></p>
      </sec>
      <sec id="article-27455.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hepatic encephalopathy is common in patients with liver cirrhosis. Depending on the etiology, it can be&#x000a0;differentiated&#x000a0;into three types:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Type A:&#x000a0;Acute liver failure</p>
          </list-item>
          <list-item>
            <p>Type B:&#x000a0;Due to portosystemic shunt in patients without any liver dysfunction&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Type C:<bold>&#x000a0;</bold>In patients with liver cirrhosis&#x000a0;</p>
          </list-item>
        </list>
        <p>The major cause of encephalopathy in all three types is the failure of ammonia to get metabolized into&#x000a0;a less toxic state by the urea cycle in portal hepatocytes&#x000a0;in the liver, either due to liver dysfunction or the development of a portosystemic shunt. The astrocyte cell membrane is highly permeable to the ammonium ion.&#x000a0;A low concentration of ammonia can cross the blood-brain barrier reaching the brain and gets deposited there. The deposition of ammonia in the brain causes a neuropsychiatric&#x000a0;syndrome.<xref ref-type="bibr" rid="article-27455.r4">[4]</xref></p>
      </sec>
      <sec id="article-27455.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The exact&#x000a0;incidence of hepatic encephalopathy among the general population is not known. It can&#x000a0;affect&#x000a0;both males and females equally and can&#x000a0;affect&#x000a0;individuals of any age.&#x000a0;It is the fourth substantial cause of death among Americans between the age of 45 and 54 years with liver disease. The hepatic encephalopathy, including minimal hepatic encephalopathy, is&#x000a0;related to 50%&#x000a0;to 70% of all patients with liver cirrhosis. The earliest form of hepatic encephalopathy is minimal hepatic encephalopathy (MHE) and can affect up to 80% of patients with liver cirrhosis.<xref ref-type="bibr" rid="article-27455.r5">[5]</xref>&#x000a0;</p>
        <p>Roughly 23%&#x000a0;to 53%&#x000a0;of individuals&#x000a0;with no liver disease but whose liver has been bypassed by a portosystemic shunt develop hepatic encephalopathy.&#x000a0;The most common cause of hepatic encephalopathy is cirrhosis, which is estimated to affect 5.5 million people in the United States.&#x000a0;Furthermore, hepatic encephalopathy is more common among nations with a higher occurrence of liver disease than the United States.</p>
      </sec>
      <sec id="article-27455.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The most important causative factor of hepatic encephalopathy is increased ammonia level in the blood. Other known neurotoxins include&#x000a0;short-chain fatty acids, mercaptans, tyramine, octopamine, manganese, and gamma-aminobutyric&#x000a0;acid (GABA).&#x000a0;Determining the blood ammonia level is complicated due to a variety of reactions taking place in multiple organs.&#x000a0;Metabolism of ammonia takes place in the liver, gastrointestinal tract, muscles, kidney, and brain. The enormous amount of ammonia produced by amino acid metabolism is captured by the urea cycle and does not contribute to blood ammonia levels under normal conditions. The primary site of production of ammonia is the gastrointestinal tract. The three main mechanisms of production of ammonia in the gut are hydrolysis of urea by bacterial urease, bacterial&#x000a0;protein&#x000a0;deamination, and glutamine metabolism in the intestinal mucosa.&#x000a0;</p>
        <p>In people with a normal healthy liver, most of this ammonia&#x000a0;produced&#x000a0;by the gastrointestinal tract is removed by the liver. Patients who develop a portosystemic shunt due to any reason like cirrhosis of the liver or, in the case of a trans-jugular portosystemic shunt, lose the first-pass metabolism of ammonia leading to hyperammonemia usually observed in patients with chronic liver disease. As this high level of ammonia crosses the blood-brain barrier, it starts depositing in brain cells leading to the neuropsychiatric syndrome.<xref ref-type="bibr" rid="article-27455.r6">[6]</xref><xref ref-type="bibr" rid="article-27455.r7">[7]</xref></p>
      </sec>
      <sec id="article-27455.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Hepatic encephalopathy can present with a wide range of signs and symptoms. Initial signs of hepatic encephalopathy can be hyperreflexia, rigidity, tremors, positive&#x000a0;Babinski's&#x000a0;sign, or asterixis (jerky movements of hands-on outstretched arms at wrists). Severe hepatic encephalopathy presents with agitation, disorientation in time-space and person, somnolence, rapidly developing confusion, and ultimately coma.<xref ref-type="bibr" rid="article-27455.r7">[7]</xref><xref ref-type="bibr" rid="article-27455.r8">[8]</xref>&#x000a0;The physical exam may demonstrate signs of chronic liver disease.</p>
      </sec>
      <sec id="article-27455.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of hepatic encephalopathy needs a thorough physical examination of the patient, followed by the categorization of signs and symptoms according to the West Haven criteria. It is important to rule out other causes of encephalopathy such&#x000a0;as viral encephalopathy,&#x000a0;intracranial lesions, masses, hemorrhage or stroke, post-seizure encephalopathy, intracranial infections, or toxic encephalopathy. The diagnosis of hepatic encephalopathy is based on four main factors:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Peculiar clinical pattern&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diagnosis of liver dysfunction or portosystemic shunt along with&#x000a0;hyperammonemia</p>
          </list-item>
          <list-item>
            <p>Alternative diagnoses ruled out</p>
          </list-item>
          <list-item>
            <p>Response of the patient to ammonia lowering therapy</p>
          </list-item>
        </list>
        <p>An electroencephalogram (EEG), computed tomography (CT) scan, and magnetic resonance imaging (MRI) of the head can be used to rule out other causes of encephalopathy.<xref ref-type="bibr" rid="article-27455.r8">[8]</xref></p>
      </sec>
      <sec id="article-27455.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Hepatic encephalopathy is a relevant cause of&#x000a0;hospitalization.&#x000a0;The management of hepatic encephalopathy involves primary and secondary prophylaxis, dietary changes, and potentially a liver transplant.</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary prophylaxis:<bold>&#x000a0;</bold>Patients with an upper GI bleed are at considerable risk of hepatic encephalopathy. Gastrointestinal lavage by mannitol or non-absorbable disaccharides reduces the risk for overt HE. Treatment of cirrhosis that reduces or reverts the progression of the disease may be considered primary prophylaxis for HE, for instance, alcohol abstinence in alcohol misusers, antiviral drugs in virus-related cirrhosis, proper nutrition in malnourished patients (both excess and deficiency), and iron overload, among others.<bold>&#x000a0;</bold>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Secondary prophylaxis:<bold>&#x000a0;</bold>It is for the patients who have suffered from episodes of hepatic encephalopathy and have a higher risk of more episodes. The use of lactulose&#x000a0;following&#x000a0;an episode decreases the risk of another episode by 50%. For those who cannot tolerate lactulose well can use rifaximin (a non-absorbable antibiotic). For patients with recurrent episodes of hepatic encephalopathy, a combination of lactulose and rifaximin can further decrease the risk of another episode. In patients who are&#x000a0;severely&#x000a0;debilitated due to disease, the goal is to find the shunt and obliterate it.</p>
          </list-item>
          <list-item>
            <p>Dietary changes:&#x000a0;For a patient with hepatic encephalopathy, the following dietary changes are advised:&#x000a0;
<list list-type="bullet"><list-item><p>The addition of snacks in between meals and before going to bed in order to reduce gluconeogenesis and catabolism of proteins.&#x000a0;</p></list-item><list-item><p>Decrease consumption of meat proteins.&#x000a0;</p></list-item><list-item><p>Try&#x000a0;replacing meat protein with milk protein.&#x000a0;</p></list-item><list-item><p>Increase the use of fiber.</p></list-item><list-item><p>Compensate for micronutrients by taking prescribed vitamins and minerals.&#x000a0;&#x000a0;</p></list-item><list-item><p>Add probiotics to the diet.<xref ref-type="bibr" rid="article-27455.r9">[9]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Patients with increased risk for aspiration or respiratory compromise should be prophylactically intubated and monitored in the ICU.&#x000a0;&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Liver Transplant:<bold>&#x000a0;</bold>Patients with hepatic encephalopathy are usually poor candidates for a liver transplant due to poor prognosis and quality of life.<xref ref-type="bibr" rid="article-27455.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27455.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Intracranial lesions such as intracranial hemorrhage, abscess, tumor, stroke, subdural hematoma</p>
          </list-item>
          <list-item>
            <p>Meningitis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypoglycemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Anoxia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Wernicke encephalopathy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Post-seizure encephalopathy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Drugs such as antipsychotics, sedatives, antidepressants<xref ref-type="bibr" rid="article-27455.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27455.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Hepatic encephalopathy is associated with a poor prognosis in terms of survival and subsequent relapses of overt hepatic encephalopathy. The quality of life for patients is poor, and there is an increased burden for caregivers. Moreover, patients have a higher risk for falls and poor driving ability, and it is associated with a lower income.</p>
      </sec>
      <sec id="article-27455.s10" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Severe confusion&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Psychomotor changes</p>
          </list-item>
          <list-item>
            <p>Disorientation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Somnolence&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cognitive changes&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Coma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27455.s11" sec-type="Consultations">
        <title>Consultations</title>
        <list list-type="bullet">
          <list-item>
            <p>Gastroenterologist</p>
          </list-item>
          <list-item>
            <p>Radiologist&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatologist&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Transplant surgeon&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hospice</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27455.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with hepatic encephalopathy can present with different signs and symptoms. The patient could present with&#x000a0;hyperreflexia,&#x000a0;rigidity, tremors, positive Babinski's sign, or asterixis in&#x000a0;initial&#x000a0;stages. Severe hepatic encephalopathy can&#x000a0;present&#x000a0;with agitation, disorientation in time-space and person, somnolence, rapidly developing confusion, and ultimately coma.&#x000a0;The newly diagnosed patient should be given emotional support and detailed information about the condition, its treatment, prognosis, and effects on everyday&#x000a0;life.</p>
        <p>The&#x000a0;patient should be provided with educational material about the disease. Flow charts, diagrams, and videos should be used to explain every aspect of the disease, treatment, and lifestyle changes. Patient education should be continued until the patient fully understands everything and is satisfied with the provision of care.</p>
      </sec>
      <sec id="article-27455.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Hepatic encephalopathy is a liver dysfunction presenting with psycho-motor signs and symptoms.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatic encephalopathy is caused by&#x000a0;acute liver failure, portosystemic shunt in patients without any liver dysfunction or in patients with liver cirrhosis due to failure of metabolism of ammonia by the liver.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Males and females are equally affected by hepatic encephalopathy.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatic encephalopathy could present with agitation, disorientation in time-space and person, somnolence, rapidly developing confusion, and ultimately coma.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diagnosis is made&#x000a0;by the categorization of signs and symptoms according to the West-Haven criteria.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Treatment usually consists&#x000a0;of primary and secondary prophylaxis with lactulose, rifaximin, and dietary changes.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hepatic encephalopathy has a poor prognosis, and patients have a poor quality of life.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27455.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>It is the responsibility of healthcare professionals that the patient has a good understanding of the disease and the appropriate treatment available for the&#x000a0;disease. Diagnosis of hepatic encephalopathy can cause significant anxiety among patients. It is vital for healthcare providers to provide&#x000a0;emotional&#x000a0;support to the newly diagnosed patient. The&#x000a0;approach&#x000a0;to hepatic encephalopathy should be with an interprofessional team,&#x000a0;including a primary clinician, pharmacist, radiologist, pathologist,&#x000a0;gastroenterologist,&#x000a0;and transplant surgeon&#x000a0;in order to provide the best care.</p>
        <p>After the diagnosis of hepatic encephalopathy is made, the prognosis is poor, and most of the patients&#x000a0;die within a year. Most patients have little knowledge about their disease, and hepatic encephalopathy can be debilitating. Thus, a consult with a home care nurse, social worker, and physical therapist is recommended to ensure the patient is receiving adequate care.</p>
      </sec>
      <sec id="article-27455.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27455&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27455">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/portal-systemic-encephalopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27455">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27455/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27455">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27455.s16">
        <title>References</title>
        <ref id="article-27455.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schenker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bay</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Portal systemic encephalopathy.</article-title>
            <source>Clin Liver Dis</source>
            <year>1997</year>
            <month>May</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>157</fpage>
            <page-range>157-84, xiii</page-range>
            <pub-id pub-id-type="pmid">15562675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27455.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franchi-Abella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gonzales</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ackermann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Branchereau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pariente</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gu&#x000e9;rin</surname>
                <given-names>F</given-names>
              </name>
              <collab>International Registry of Congenital Portosystemic Shunt members</collab>
            </person-group>
            <article-title>Congenital portosystemic shunts: diagnosis and treatment.</article-title>
            <source>Abdom Radiol (NY)</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>8</issue>
            <fpage>2023</fpage>
            <page-range>2023-2036</page-range>
            <pub-id pub-id-type="pmid">29730740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27455.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Philips</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Rajesh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Augustine</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Padsalgi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ahamed</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options.</article-title>
            <source>Hepat Med</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>23</fpage>
            <page-range>23-34</page-range>
            <pub-id pub-id-type="pmid">30774483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27455.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiati Kenston</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Mechanistic insight, diagnosis, and treatment of ammonia-induced hepatic encephalopathy.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-39</page-range>
            <pub-id pub-id-type="pmid">30070387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27455.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nardone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>H&#x000f6;ller</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Brigo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lochner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Trinka</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Minimal hepatic encephalopathy: A review.</article-title>
            <source>Neurosci Res</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>111</volume>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">27153746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27455.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levitt</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Levitt</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>A model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism, and excretion of ammonia in humans.</article-title>
            <source>Clin Exp Gastroenterol</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>193</fpage>
            <page-range>193-215</page-range>
            <pub-id pub-id-type="pmid">29872332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27455.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferenci</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hepatic encephalopathy.</article-title>
            <source>Gastroenterol Rep (Oxf)</source>
            <year>2017</year>
            <month>May</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>138</fpage>
            <page-range>138-147</page-range>
            <pub-id pub-id-type="pmid">28533911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27455.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amodio</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hepatic encephalopathy: Diagnosis and management.</article-title>
            <source>Liver Int</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>966</fpage>
            <page-range>966-975</page-range>
            <pub-id pub-id-type="pmid">29624860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27455.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vilstrup</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Amodio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bajaj</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cordoba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferenci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mullen</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Weissenborn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.</article-title>
            <source>Hepatology</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>715</fpage>
            <page-range>715-35</page-range>
            <pub-id pub-id-type="pmid">25042402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27455.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patidar</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Bajaj</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>2048</fpage>
            <page-range>2048-61</page-range>
            <pub-id pub-id-type="pmid">26164219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27455.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marois</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Quirins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mouri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bouzbib</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rudler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thabut</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>[Metabolic encephalopathies].</article-title>
            <source>Rev Med Interne</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>88</fpage>
            <page-range>88-97</page-range>
            <pub-id pub-id-type="pmid">30638703</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
